S_mary Photodynamic therapy (PDT) has the potential to destroy small tumours with safe healing of adjacent normal tissue. This study looks at the effects of PDT on the normal pancreas and adjacent tissues in hamsters using the photosensitiser meso-tetrahydroxyphenylchlorin (mTHPC). Pharmacokinetic studies used fluorescence microscopy on sections of pancreas, stomach and duodenum 1 h to 6 days after mTHPC. Highest levels of sensitiser were seen in the gastric and duodenal mucosa and in the acinar pancreas after 2-4 days. For PDT, light at 652 nm was delivered by placing a 0.2 mm diameter bare-ended fibre against the tissue. An energy of 50 J was used 2 or 4 days after 0.1 or 0.3 mg kg-l mTHPC and animals killed I to 7 days later.
Photodynamic therapy (PDT) involves the local activation of a preadministered photosensitiser by light of a wavelength matched to the absorption characteristics of the photosensitiser. The activated photosensitiser gives rise to the production of cytotoxic singlet oxygen (Weishaupt, 1976) . In many publications it has been shown that it is relatively easy to destroy small volumes of a wide variety of tumours with PDT (Li et al., 1990 . However, what matters to a patient is whether the entire tumour volume can be destroyed without unacceptable damage to adjacent normal tissues. This means that it is essential to understand what happens in the region where tumour is invading normal areas.
Until now little work has been done on this aspect (Bown, 1990) . Although much of the interest in PDT has centred around the possibility of selective destruction of tumours, this aspect is almost always over emphasised, and truly selective destruction of cancers is virtually impossible (Barr et al., 1990 . Many normal tissues heal mainly by regeneration after PDT, but for tissues like muscle, there is only partial restoration of function (Chevretton et al., 1992) . A previous report (Schroder et al., 1988) showed that PDT will produce necrosis in a chemically induced pancreatic cancer in hamsters using dihaematoporphyrin ether (DHE) but at the price of duodenal perforation. The most studied photosensitiser, haematoporphyrin derivative (HpD) and purified fractions thereof (like DHE) are unfortunately far from ideal. Sulphonated metallophthalocyanines are better (Bown et al., 1986; Paquette et al., 1988; Peng et al., 1990; Nuutinen et al., 1991) . Their advantages include absorption above 650 nm (giving better light penetration in tissue), photochemical and thermal stability in solution, relatively welldefined chemistry and less skin photosensitisation (Roberts et al., 1989; Tralau et al., 1989 phthalocyanine (AlS2Pc) is a more potent photosensitiser than the tetrasulphonated derivative both in vitro and in vivo (Chan et al., 1990; Chatlani et al., 1991) and has been studied in normal pancreas and adjacent tissues in Syrian golden hamsters (Nuutinen et al., 1991) . The results were similar to those seen with DHE.
Recently, 5-aminolaevulinic acid (5-ALA) has been used as precursor for the photosensitiser protoporphyrin IX in studies on PDT in tumours transplanted into the pancreas of Syrian golden hamsters (Regula et al., 1994) . The results were promising with the fluorescence ratio between tumour and normal being up to 8:1, PDT necrosis up to 8 mm in diameter being observed in the tumour, with no evidence of duodenal perforations. Several other photosensitisers are now being studied, based on three main types of compoundsmodified porphyrins, chlorins and phthalocyanines.
One of particular interest is meso-tetrahydroxyphenyl chlorin (mTHPC) which was developed at Queen Mary's College, London, in 1987 (Berenbaum et al., 1986 Bonnett et al., 1990; Bonnett, 1993) and is the one used in the present study. As the testing of various new photosensitisers proceeded, it was noticed that favourable selectivity was associated with amphiphilic porphyrins (Bonnett et al., 1989) . The porphyrin macrocycle itself is hydrophobic and so hydrophilic substituents were needed. Various water-solubilising groups were tried, particularly SO3H and OH. It was found that hydroxy phenyl meso-substitution of a porphyrin gave compounds which showed interesting activity and selectivity in tumour necrosis. Several compounds of this type were prepared-the meta (m-THPP), ortho (o-THPP) and para (p-THPP) isomers. Increased absorption in the red was achieved by converting the m-THPP by reduction with diamide into the chlorin m-THPC and into the bacteriochlorin m-THPBC. mTHPC is readily prepared in three stages from pyrrole and m-metroxybenzaldehyde (Bonnett. 1993) . It is a pure compound with an absorption peak at 650 nm (Bonnett et al., 1989) (H & E) for later visual comparison using light microscopy and photography. The combination of phase-contrast microscopy of the frozen sections and light microscopy of H & E stained adjacent tissue sections enabled different structures of the tissues (mucosa, submucosa, muscle, serosa, pancreatic parenchyma and acinar pancreas) to be identified in the fluorescence image and the fluorescence intensity of these structures to be measured .
Photodynamic therapy
The light source used was a pulsed (12 kHz) copper vapour pumped dye laser (Oxford lasers, Oxford, UK) at a wavelength of 650 nm, which corresponds to a main absorption peak of mTHPC. Light was delivered via a 0.2 mm bare-end fibre just touching the surface of the tissue to be irradiated at laparotomy. As this gives a very high light irradiance at the fibre tip (160 W cm-2 for 50 mW), unsensitised control animals were treated first with light at 50 mW and 100 mW to exclude any significant thermal effects. Light at 100 mW gave considerable thermal effects, but 50 mW did not, so all the PDT experiments were undertaken using 50 mW with an exposure time of 1000 s (50 J). The sites treated were the duodenal lobe of the pancreas, antral part of the stomach, upper duodenum (adjacent to the pancreas and bile duct, but clear of the ampullary region) and the free edge of the lesser omentum. Only one site was treated in each animal. Two animals were studied for each combination of variables (drug dose, time from drug to light and time from PDT to sacrifice). The experiments were divided into five groups. The total delivered energy was 50 J (50 mW for 1000 s) in each case, given as a single fraction except in some animals in group 5.
(1) Light was given 2 or 4 days after sensitisation with 0.3 mg kg-' mTHPC. Only the pancreas was treated and animals were killed 1, 2, 3, 4 and 7 days after treatment to detect the time of maximum necrosis. (2) Light was given 2 or 4 days after sensitisation with 0.3 mg kg-' mTHPC. The areas treated were the pancreas, stomach, duodenum and free edge of lesser omentum. Animals were killed 3 days after treatment (found from section 1 to be the time of maximum necrosis). (3) Light was given 2 or 4 days after sensitisation with 0.1 mg kg-' mTHPC. This lower dose of mTHPC was used to see if it would reduce the incidence of duodenal perforation and bile duct stenosis. The areas treated were the pancreas, stomach, duodenum and free edge of lesser omentum and the animals were killed after 3 days. (4) Light was given 4 days after sensitisation with 0.1 mg kg -mTHPC. The areas treated were the pancreas and the free edge of the lesser omentum but with 'shielding' of the duodenum by gentle mobilisation and insertion of a piece of opaque paper between the duodenum and the fibre tip (Nuutinen et al., 1991) . Animals were killed 3 days after PDT. (5) Light was given either as a single fraction (as in sections 1-4) or in four equal fractions with breaks between fractions of either 1 or 3 min. Light was given 2 or 4 days after sensitisation with 0.3 mg kg-' mTHPC. Only the pancreas was treated and animals were killed 3 days after PDT.
In all cases. when the animals were killed, the treated tissues were studied macroscopically to measure the greatest and smallest diameter of necrosis and the mean diameter calculated before microscopic examination.
Results
Fluorescence microscopy Fluorescence was measured in arbitrary units of counts per pixel corrected for background levels using sections from control animals. The relative levels of mTHPC in the different regions of the pancreas. stomach and duodenum are shown in Figure 1 . In all the tissues studied, the highest levels of mTHPC fluorescence were seen 4-5 days after PDT with mTHPC around the pancreas P Mlkvy et al 1475 sensitisation. In most of the areas studied. there was a lesser peak at 2 days although the number of animals studied was not large enough to be sure how significant the dip at 3 days is. It is most likely due to statistical variations. The estimated errors in the fluorescence readings are + 15o%. days. the levels declined rapidly in all tissues except the pancreatic parenchyma where they fell more slowly. In the stomach and duodenum. levels were highest in the mucosa and serosa and lower in the submucosa and muscle (the duodenal muscle was too thin to make accurate measurements).
Phototherapv studies In control animals (no mTHPC) treated w-ith 50 J of light there were no effects on the duodenum or stomach at the power level of 50 mW. with only verv minor changes in the pancreas (oedema and necrosis up to 1.0 mm in diameter). In contrast. if the power was increased to 100 mW. there was ulceration up to 2.1 mm in the duodenum and 1.5 mm in the stomach and necrosis up to 2.0 mm in the pancreas. seen in animals killed 3 days after treatment. Consequentl,. the power was limited to 50 mW for all subsequent experiments.
Based on the results of the fluorescence studies. for PDT. light was given on the second or fourth day after sensitisation in all animals. The results from group 1 looking at the extent of necrosis at different times after treating the pancreas are shown in Figure 2 . The maximum size of PDT lesion was seen at 3 days, and so in the subsequent experiments animals were killed 3 days after PDT. Despite the differences in the fluorescence levels 2 and 4 days after sensitisation, there was no difference in the size of lesions obtained by treating at these different times. and there was no evidence of free perforation of the bile duct. Dilatation was also seen in some of the animals treated on the free edge of the lesser omentum, but not for any other treatment sites, nor when the duodenum was shielded. These findings are shown in Table II . When the tip of the fibre was situated in the duodenal lobe of the pancreas it lay approximately 3 mm from the duodenal wall, 5 mm from the abdominal aorta and 7 mm from the inferior vena cava, and in the free edge of the lesser omentum was immediately adjacent to the bile duct. These findings suggested temporary biliary obstruction which resolved without serious sequelae by the seventh day. No perforation of the bile duct or gall bladder was seen. No biliary obstruction was seen in the animals treated on the duodenum further away from the ampulla, so the obstruction was most likely due to oedema at the ampulla.
No necrosis was seen in the stomach in animals whose pancreas had been treated, even if the tip of the fibre was placed in the duodenal lobe of the pancreas only about 3 mm from the greater curve of the stomach. When the stomach was treated directly, ulceration was found but there were no gastric perforations. There was no macroscopic evidence of damage to the liver parenchyma or major blood vessels (portal vein, vena cava, abdominal aorta and hepatic artery).
It was because of these complications of PDT with 0.3 mg kg-' mTHPC that the further series of animals were sensitised with the lower dose of 0.1 mg kg -' and then treated with the same light dose of 50 J. The dimensions of the lesions produced with each dose are shown in Figure 3 . With the smaller dose, smaller lesions were seen in the pancreas and only one animal showed any evidence of bile duct obstruction (Table II) , but sealed duodenal perforations were still seen in half the animals treated on the pancreas or free edge of lesser omentum. Perforations could only be avoided by shielding the duodenum during treatment (Table   I ).
The group 5 experiments were designed to assess the possibility of increasing the PDT effect by fractionating the light without increasing the total dose delivered. The only site treated was the pancreas. The results are shown in Figure 4 . In both groups of animals with fractionated therapy (three breaks of either 1 or 3 min) there was an increase of more than 30% in the lesion size compared with animals receiving the same light dose in a single fraction.
Macroscopically, necrosis in the pancreas had a yellowish white appearance with surrounding oedema. Microscopically, there were sharply demarcated areas of necrosis ( Figure 5 ). Acute inflammatory changes were seen in the first couple of days with lymphocytes and plasma cells by day 3. After 7 days, there was a ring of fibrous tissue around the necrosed area. Without shielding, necrosis of all layers of the duodenal wall was seen close to the treated area ( Figure 6 ) and even 10-15 mm away, inflammatory changes were found in the distal duodenum, proximal jejunum and in the gall bladder. In the stomach, mucosal ulceration was seen with inflammatory changes in the submucosa, but there were no perforations. There were four animals in each group, two treated 2 days and two treated 4 days after administration of mTHPC (only two animals for each site, both treated at 4 days, in the shieled duodenum group). All animals received 0.3 mg kg-l mTHPC except those in the final column which only received 0.1 mgkg-'. The figure given is the number of animals in which there was macroscopic evidence of a dilated common bile duct. No animals showed any evidence of free perforations of the bile duct.-, no animals treated at this site with this dose. Duodenum and pancreas 3 days after PDT using 0.1 mgkg'1mTHPC 2 days before 50 J of light Full-thickness necrosis of the duodenal wall is seen (arrow). Macroscopically, this animal had a sealed perforation of the duodenum. Scale: 1.3 x 1.0mm.
Dis assi
Photodynamic therapy has attracted most interest because of the possibility of selective destruction of tumours. Undoubtedly there is some selectivity in the uptake of various photosensitisers in malignant tissue, but unfortunately it is much more difficult to achieve selective necrosis with any of the photosensitisers currently available when tumour and normal tissue are exposed to the same light dose. Thus it is essential to understand how normal tissues respond to PDT. As a first step, it is important to know the microscopic distribution of the photosensitiser, which can be done using fluorescence microscopy. Considerable differences exist between different sensitisers. The present work has shown that mTHIPC levels are highest in the mucosa and serosa of the stomach and duodenum and in the acinar pancreas and lower in the submucosa. In contrast, AlS2Pc levels were highest in the submucosa and bile duct, but low in the acinar pancreas (Nuutinen et al., 1991) . Using aminolaevulinic acid (ALA), the situation was different again, the levels of the active derivative, PPIX, being highest in the mucosa but low in the pancrea (Regula et al., 1994; Loh et al., 1993) . Low levels were seen in muscle with all these photosensitisers. Comparable data are not available for HpD or DHE.
By far the most vulnerable organ in our experiments was the duodenum. The highest levels of mTHPC in the duodenum were in the mucosa, and for ALS2Pc were in the submucosa, but for both, duodenal perforations were seen in many animals and could only be avoided by shielding the duodenum during light exposure (Nuutinen et al., 1991) . The most likely explanation is that both the submucosa and the muscle layer of the hamster duodenum are extremely thin (0.06-0.3 mm) which would make them more vulnerable than the stomach. Earlier work has shown that the main mechanical strength of the colon after PDT damage comes from collagen in the submucosa (Barr et al., 1987) , and the same is likely to be true in the duodenum. One Thus PDT with mTHiPC in the normal hamster can produce necrosis in normal pancreas, biliary tree, stomach and duodenum, but the only organ in which this necrosis produces serious complications that do not resolve spontaneously is the duodenum.
Our main target is to treat tumours of the pancreas. From results with other photosensitisers, it is likely that using mTHPC there will be at least as much necrosis in pancreatic cancers as in the adjacent normal pancreas (Schroder et al., 1988; Chatlani et al., 1992; Regula et al., 1994) , and we have shown that with the lower dose of sensitiser and shielding of the duodenum, perforation can be prevented. Also, the human duodenum is much thicker than that in the hamster, so may be much more resistant to perforation. Recent clinical reports using PDT with HpD to treat ampullary tumours showed a reasonable response with no perforations (Abulafi et al., 1995; Mlkvy et al., 1995 Veen et al., 1994) have shown that the effect of PDT can be enhanced by fractionating the light dose. The results in the present study have confirmed this for the first time using mTHPC as the photosensitiser. The fractionation regimens that we used were chosen fairly arbitrarily (four equal fractions with breaks between fractions of either 1 or 3 min), but the diameter of necrosis produced in the pancreas was increased by about 30% compared with the effect of the same light dose given as a single fraction (Figure 6 ). The most likely mechanism is that the break permits reoxygenation of the tissues being treated. However, these are only preliminary findings and further studies are necessary to optimise this effect, particularly by varying the timing, duration and number of breaks.
We conclude from these studies that most normal tissues in the region of the pancreas can tolerate PDT with mTHPC as the photosensitiser. There is a risk of perforation of the duodenum in hamsters, but this is likely to be much less in humans. There is also a risk of biliary stenosis, but this appears to be reversible. Further studies on an animal model of pancreatic cancer are now indicated before preliminary clinical trials.
